4CPS-178 Descriptive analysis in real-world of treat and extend treatment of faricimab in patients failing prior intravitreal treatments

<h3>Background and Importance</h3> Faricimab is a monoclonal antibody that blocks vascular endothelial growth factor (anti-VEGF) A and angiopoietin-2, approved to treat wet age-related macular degeneration (AMD), diabetic macular oedema (DME) and macular oedema following retinal vein occlusion. The improvement and maintenance of visual outcomes (improvements in visual acuity) and anatomical outcomes (decreased central retinal thickness and resolution of exudative disease (decrease intraretinal or subretinal fluid) drive the frequency of intravitreal injections. In a treat-and-extent (T&amp;E) regimen, after an initial loading phase of four doses of faricimab given, patients are injected at different intervals until improvement in visual and anatomic outcomes is achieved. <h3>Aim and Objectives</h3> To evaluate the real-world T&amp;E regimen with faricimab in patients with wet AMD and DME following the failure of prior treatment lines and to monitor their clinical outcomes. <h3>Material and Methods</h3> A unicentre, observational, descriptive and retrospective study from September 2023 to September 2024. Collected variables included demographics (age, sex), diagnosis, previous treatments, number of doses and frequency, reasons for discontinuation and side effects of faricimab. After loading doses, treatment intervals can be extended to 4 weeks up (Q8) to 12 (Q12) or to 16 (Q16) weeks if there is an improvement in visual and/or anatomical outcomes. Data were extracted from medical records. <h3>Results</h3> We included 132 patients (52% male, 48% female) with a mean age 77 ± 10 years and a total of 169 eyes. 78 eyes were previously treated with one anti-VEGF, 67 eyes with two and 24 with three or more therapies. 56% (94 eyes) with Wet AMD: 60% are in loading dose, 25% in Q8, 3% in Q12, 1% in Q16 and 11% were ineffective. 44% (75 eyes) with DME: 69% are in loading dose, 4% were monthly, 12% in Q8, 3% in Q12 and 12% were ineffective. Side effects were not reported. <h3>Conclusion and Relevance</h3> Faricimab at our hospital is an alternative T&amp;E regimen for wet AMD and DME patients who are resistant to other anti-VEGF. In wet AMD 28% eyes and in DME 19% eyes were in T&amp;E regimen. In both diagnoses, approximately 11% of cases were ineffective. Our experience indicates the importance of long-term follow-up. The treatment was generally well tolerated, with no significant safety issues reported. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest